Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 146 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose CT scan Clear all

Conditions: Lung Cancer
Interventions: low-dose helical computed tomography, chest radiography; Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 55 Years to 74 Years
Enrollment: 53,454 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2010
U.S. locations: 33
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 29 more

Conditions: Solitary Pulmonary Nodule, Multiple Pulmonary Nodules
Interventions: Not listed
Lead sponsor: Fresh Medical Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • Stanford, California + 12 more

Conditions: Hepatocellular Carcinoma
Interventions: F18-FDG, MRI, CT, F18-DCFPyL, Tumor biopsy; Drug · Device · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alzheimer Disease
Interventions: Challenge A - low calorie Ensure®, Challenge B - Ensure® plus ketone esters (KE), PET Scan, Cognitive Testing - FCSRT, Story Recall, BVRT, CogState One Card Learning; Dietary Supplement · Procedure · Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Prostate Cancer, Prostate Neoplasm, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Metastatic Prostate Cancer
Interventions: 18F-DCFPyL-iPSMA, 68Ga-HBED-iPSMA, PET/CT scan; Drug · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Healthy Volunteer, Bone Alteration, Bone and Joint Cancer, Bone and Joint Infection, Arthritis
Interventions: 18F-NaF; Drug
Lead sponsor: Akiva Mintz; Other
Eligibility: 18 Years to 120 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Englewood, New Jersey

Conditions: Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions: Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation; Radiation · Drug · Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 5
States / cities: Gainesville, Florida • Chapel Hill, North Carolina • Hendersonville, North Carolina + 2 more

Conditions: Multiple Pulmonary Emboli
Interventions: Low-Dose IV Contrast, Siemens Sensation 64-MDCT scanner., Visipaque 320 non-ionic isoosmolar contrast agent; Procedure · Device · Drug
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Acute Myeloid Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 6 Months to 21 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 186
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more

Conditions: Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult
Interventions: Epcoritamab, Rituximab; Drug
Lead sponsor: Reid Merryman, MD; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Rochester, New York + 2 more

Conditions: Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Mosunetuzumab, Positron Emission Tomography, Questionnaire Administration; Procedure · Biological · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor
Interventions: 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Chest Radiography, Computed Tomography, Dactinomycin, Doxorubicin Hydrochloride, Echocardiography Test, Magnetic Resonance Imaging, Therapeutic Conventional Surgery, Ultrasound Imaging, Vincristine Sulfate; Radiation · Procedure · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 29 Years
Enrollment: 808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2026
U.S. locations: 210
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 150 more

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Coronary Artery Calcium Scan, Carotid Artery Ultrasound, Lipoprotein(a) Measurement, Vascular Function Testing; Diagnostic Test
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Thoracic Cancer, Abdominal Cancer
Interventions: Tidal volume measured by spirometer and DIBH surface from CT image; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Lung Cancer, Tobacco Use, Homelessness
Interventions: Patient Navigation; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 55 Years to 77 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lung Cancer
Interventions: chest x-ray with or without CAD, lose dose CT scan; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 40 Years to 75 Years
Enrollment: 1,424 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy (Controls), Healthy Volunteers, Neuroendocrine (NE) Tumors
Interventions: 68Ga-Dotatate; Drug
Lead sponsor: Akiva Mintz; Other
Eligibility: 18 Years to 120 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Englewood, New Jersey

Conditions: Smoking
Interventions: Usual Care, WEB+TXT, WEB+TXT+TTS; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Osteoporosis
Interventions: Quantitative computed tomography scan for bone density analysis; Radiation
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 50 Years and older · Female only
Enrollment: 197 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Radius Fractures
Interventions: Low Dose CT Scan of the Wrist; Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Lung Cancer Screening, Tobacco Use Disorder, Smoking Cessation
Interventions: Smoking cessation multilevel Intervention; Behavioral
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 50 Years to 80 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: New Orleans, Louisiana

Conditions: Melanoma, Neuroblastoma, Sarcoma
Interventions: 124I-Humanized 3F8; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 3 Years to 90 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer
Interventions: cisplatin, etoposide, tirapazamine, radiation therapy; Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 87
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more

Conditions: Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Proton Beam Radiation Therapy, Radiation Therapy, Stereotactic Body Radiation Therapy; Radiation · Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

National Lung Screening Trial (NLST) Screening

A Multi-Center Trial of the ProLung Test™

18F-DCFPyL PET/CT in Hepatocellular Carcinoma

The Brain Ketone Body Challenge Imaging Study

Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer

Ultralow Dose PET Imaging for 18F-NaF Uptake

De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study

Efficacy of Low (30ml) Versus Full Dose (100ml) Contrast CT Pulmonary Angiography in Detecting Emboli

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Epcoritamab and Rituximab for First-line Follicular Lymphoma

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFE

VisionRT-based Deep Inspiration Breath-hold (DIBH) Respiratory Motion Management Strategy, A Pilot Study for Thoracic and Abdominal Tumors

Lung Cancer Screening Navigation for Homeless People

Chest Imaging, Breath, and Biomarkers in a Screening Trial

Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

Low Dose Computed Tomography for Lung Cancer Screening

Salivary-based Bone Loss Marker Detection Platform for Point-of-care Screening - Phase II Study

Low Dose CT Distal Radius Fractures

Multilevel Intervention for LDCT Lung Cancer Screening and Smoking Cessation Among African Americans

PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study

S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer

Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer